[go: up one dir, main page]

WO1999058160A1 - The use of a vital dye for facilitating surgical procedures for cataract extraction - Google Patents

The use of a vital dye for facilitating surgical procedures for cataract extraction Download PDF

Info

Publication number
WO1999058160A1
WO1999058160A1 PCT/NL1999/000284 NL9900284W WO9958160A1 WO 1999058160 A1 WO1999058160 A1 WO 1999058160A1 NL 9900284 W NL9900284 W NL 9900284W WO 9958160 A1 WO9958160 A1 WO 9958160A1
Authority
WO
WIPO (PCT)
Prior art keywords
dye
capsule
anterior
staining
lens capsule
Prior art date
Application number
PCT/NL1999/000284
Other languages
French (fr)
Inventor
Gerrit Reinold Jacob Melles
Original Assignee
Gerrit Reinold Jacob Melles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8233705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1999058160(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DE69905871T priority Critical patent/DE69905871T2/en
Priority to AT99921291T priority patent/ATE234118T1/en
Priority to BR9910287-0A priority patent/BR9910287A/en
Priority to EP99921291A priority patent/EP1075285B1/en
Priority to AU38537/99A priority patent/AU758951C/en
Application filed by Gerrit Reinold Jacob Melles filed Critical Gerrit Reinold Jacob Melles
Priority to CA002331605A priority patent/CA2331605C/en
Priority to DK99921291T priority patent/DK1075285T3/en
Priority to PL99343924A priority patent/PL194442B1/en
Priority to JP2000548011A priority patent/JP3469199B2/en
Priority to SI9930298T priority patent/SI1075285T1/en
Publication of WO1999058160A1 publication Critical patent/WO1999058160A1/en
Priority to US09/708,386 priority patent/US6720314B1/en
Priority to AU2003208122A priority patent/AU2003208122A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Definitions

  • the invention relates to the field of ocular surgery, in particular to surgical procedures for cataract extraction.
  • the crystalline lens In the normal eye, the crystalline lens is located behind the iris, and in front of the corpus vitreum.
  • the lens is transparent, biconvex, accounts for about 20 diopters of convergent refractive power of the eye, and it is composed of a capsule that encloses and encompasses the lens substance, i.e. the lens epithelium, the cortex, and the nucleus.
  • the capsule is an elastic, type IV collagen basement membrane produced by the lens epithelial cells.
  • the thickness of the capsule varies from 4-24 ⁇ m, with a thickness of about 14 ⁇ m at its anterior part, 24 ⁇ m at its equatorial part, and about 4 ⁇ m at its posterior part. Because of its transparency, and because its refractive index nearly equals the lens substance, the lens capsule can not be discriminated from the lens substance, except with the use of a slit-lamp at high magnification.
  • the lens substance may become less transparent, i.e. a cataract may develop, due to aging or to a wide variety of ocular or systemic pathological disorders or diseases. Affected portions of the lens substance may differ with the type of disorder, but in most cases the optical and/or refractive functions of the lens are compromised, for example a decreased visual acuity, a decreased contrast sensitivity, an accommodation loss, etc.
  • cataract surgery may be performed to remove the opaque lenticular mass.
  • various surgical techniques are available, extracapsular cataract extraction techniques, the Blumenthal technique, or phacoemulsification are most often used.
  • the anterior chamber of the eye is opened through a peripheral corneal, limbal or scleral incision, the anterior lens capsule is opened, and the lens substance is removed, while leaving the peripheral rim of the anterior lens capsule as well as the capsular equatorial and posterior portions in-situ.
  • the empty lens capsule forms a capsular 'bag' that can be used to support a synthetic intraocular implant lens (IOL) , so that an IOL is positioned 'in the bag 1 .
  • IOL intraocular implant lens
  • Various techniques are used to open the anterior lens capsule, i.e. the excision of a portion of the anterior lens capsule, with or without the use of a viscous or viscoelastomeric substance, for example the can-opener technique, the envelop technique, the capsulotomy, and the continuous circular capsulorhexis.
  • a viscous or viscoelastomeric substance for example the can-opener technique, the envelop technique, the capsulotomy, and the continuous circular capsulorhexis.
  • the red fundus reflex the co-axial light of an operating microscope that is reflected from the posterior pole of the eye, is commonly used.
  • retroillumination is absent, for example with dense cataracts, heavily pigmented fundi or a combination of both, it is often not or only hardly possible to discriminate the anterior capsule from the underlying lens tissue.
  • Visualization of the defect in the anterior capsule during the opening of the lens capsule is an important step in the surgical procedure, because the mechanical traction forces which the capsule can withstand during surgery, vary with the configuration of the capsular opening.
  • a continuous circular capsulorhexis is commonly performed, because a circular configuration of the capsular opening can withstand best the surgical manipulations within the lens capsule during the removal of the lens substance.
  • Improper visualization of the anterior lens capsule during the performance of a capsulorhexis may be responsible for a risk of a radial tear toward or beyond the equator of the lens capsule, and associated complications, for example vitreous loss, or a dropped nucleus.
  • the outline of the opening in the anterior lens capsule is often difficult to visualize.
  • a useful red fundus reflex is nearly always absent, because the lenticular tissue becomes opaque.
  • an inadvertent touch of the rim with the tip of the phacoemulsification hand piece or an overextension of the capsule during dividing the lenticular substance may damage the rim of the capsulorhexis.
  • the damaged rim may give a greater risk of a radial tear toward the equator and associated complications, especially because the damage to the rim of the capsulorhexis may not be noticed during surgery .
  • the rim of the anterior capsule must be visualized to place the haptics of the IOL in between the anterior and posterior portions of the lens capsule.
  • the anterior capsular rim can often be seen with the use of the red fundus reflex.
  • the IOL is manipulated in such a way that the displacement of the capsular rim by the haptic or optic of the IOL indicates the position of the IOL relative to the capsule.
  • a useful red fundus reflex is absent, as mentioned above, it becomes difficult to determine the position of the IOL relative to the capsule.
  • Fluorescein is a dye which is capable of diffusing through various tissue structures (see e.g. Brubaker RF, "Clinical evaluation of the circulation of aqueous humor", in Tasman W, Jaeger EA, “Duane's clinical Ophthalmology", Volume 3, Chapter 46, Philadelphia, JB Lippencott Co, 1994:1-11; or Friberg TR, "Examination of the retina: principles of fluorescein angiography” , in Albert DM, Jakobiec FA, “Principles and practice of ophthalmology", Volume 2, Philadelphia, WB Saunders Co, 1994 ; 697-718.) .
  • fluorescein when used as suggested by Hoffer and McFarland, fluorescein will not only stain the anterior lens capsule, but also the material below said capsule, particularly as the fluorescein is injected underneath the anterior lens capsule. This means that both the anterior lens capsule as well as the underlying lenticular tissue are stained by the fluorescein dye. Thus, no difference in staining can be observed between the anterior capsule and the underlying tissue during the capsulorhexis, and the desired improved visibility is not, or not sufficiently, achieved. Moreover, it was noted by Hoffer and McFarland that the sodium hyaluronate, which is used during the operation to fill the anterior chamber of the eye, may become stained and may have to be replaced with fresh sodium hyaluronate . Of course, it is undesired to have to interrupt the course of the surgical procedure to replace the gel layer.
  • the present invention seeks to overcome the above described problems associated with poor visibility of the lens capsule during cataract surgery. It is an object of the invention to make it possible to visually distinguish the anterior lens capsule from the underlying lenticular material, so that the configuration of an opening in the anterior lens capsule can be better monitored during surgery, for example to prevent the development of a radial tear toward or beyond the equator of the lens capsule during the performance of a capsulorhexis.
  • the invention relates to a method for performing a capsulorhexis, wherein an anterior lens capsule is stained using at least one dye, which dye is capable of staining tissue without noticeably diffusing into said tissue.
  • the outer surface of the anterior lens capsule is selectively stained, by which is meant that the lenticular material beneath the anterior lens capsule, is not noticeably stained. Accordingly, during the opening of the anterior lens capsule, a clear distinction can be observed between the portion of the anterior lens capsule, that is being removed, and the underlying lenticular material. This distinction facilitates the controlled opening of the anterior capsule, and reduces the risk of inadvertent damage to the capsule, for example a radial tear toward or beyond the equator of the lens .
  • the anterior lens capsule is stained using a dye.
  • a dye is used which is capable of staining tissue without diffusing into or through said tissue. Suitable dyes having this capability further should have sufficient coloring, or staining capacity at concentrations which are physiologically and toxicologically acceptable.
  • the minimum amount of dye which is necessary to provide sufficient staining for a useful coloring to be visible should so be low that no, or hardly any, adverse toxic effects occur.
  • the dye is not or hardly endothelial toxic. It is further preferred, that substantially no traces of the dye are present in the eye, shortly after the cataract extraction procedure has been completed. As a result, there is hardly any risk of the patient experiencing any irritation of the cornea (corneal edema) or another part of the eye.
  • R. and R 2 are the same or different arylgroups, and wherein R 3 and R 4 are independently chosen from hydrogen, methyl, ethyl, methoxy, amino, hydroxyl , and sulfonate.
  • R. and R 2 are preferably the same and formed by substituted naphtylgroups .
  • the naphtylgroups are substituted with one or more of sulfonate groups, amino groups and hydroxyl groups .
  • the dye is chosen from the group of trypan blue, trypan red and brilliant crysyl blue. It has been found that these dyes provide a clearly visible staining at very low amounts. Also, they have an extremely advantageous toxicity profile. More preferably, the dye is trypan blue.
  • the dye is preferably used as a physiologically compatible solution.
  • the dye is formulated in an aqueous salt solution, which is isotone with ocular fluid.
  • the salt is preferably sodium chloride, sodium phosphate, potassium chloride, calcium chloride, magnesium chloride, or a combination thereof. Suitable examples are Balanced salt solution or Hartmann's lactated Ringer's solution (Nuijts RMMA, Edelhauser HF, Holley GP, "Intraocular irrigating solutions: a comparison of Hartmann's lactated Ringer's solution, BSS and BSS plus", Clin. Exp . Ophtamol . , vol. 233 (1995), pp. 655-661).
  • the salt concentration will be in the range of 0.8 to 1.0 wt.%, based on the weight of the solution.
  • the solution has a neutral pH, i.e. a pH between 6.5 and 7.5.
  • a suitable buffer which has the properties to be of use in opthtalmic applications.
  • An example of a suitable buffer is phosphate buffered NaCl , commercially available at NPBI , Emmer-Compascuum, The Netherlands
  • said solution may be desired to formulate said solution as a dispersion, or a viscous or viscoelastomeric solution, for example hyaluronic acid (see WO-A-96/32929) .
  • a viscous or viscoelastomeric solution for example hyaluronic acid (see WO-A-96/32929) .
  • hyaluronic acid see WO-A-96/32929
  • a suitable form for the solution For instance, a higher viscosity may be desired in order to reduce the tension on the lenticular capsule during the capsulorhexis or to protect the cornea.
  • the concentration of the dye or the mixture of dyes in the solution will preferably be between 0.001 and 2 wt.%, more preferably between 0.01 and 0.1 wt.%, based on the weight of the solution. Within this range, the concentration may be adapted to the toxicity and coloring characteristics of the dye used. It is preferred that such an amount is chosen that an optimal staining effect is achieved, while at the same time the risk of possible damage to the eye or any part thereof due to the toxicity of the dye is minimized.
  • a method according to the invention is preferably employed as part of a surgical procedure for cataract extraction.
  • the aqueous (ocular fluid) is aspirated and the anterior camber is filled with air.
  • a few drops of the above described solution comprising the dye in an appropriate concentration is applied onto the anterior lens capsule.
  • the application of the solution may be carried out by bringing a canula that is attached to a syringe containing the dye into the anterior chamber, and to inject a few drops of the dye, generally less than 1 ml, onto the anterior lens capsule.
  • the anterior chamber is filled with air, so that the concentration of the dye in the solution is not lowered by the aqueous.
  • the dye can be administered in a higher concentration into the aqueous, or a dispersion of the dye in a viscous or viscoelastomeric solution can be used.
  • the excess dye is washed out by irrigating the anterior chamber, leaving a faint but clear staining of the anterior lens capsule, after which the surgery can be continued using routine techniques.
  • the irrigation may be carried out by using Balanced salt solution or any other solution that is commonly used in intraocular surgical procedures .
  • the capsule can be opened using routine surgical techniques. Independent of whether a red fundus reflex is present, the defect in the capsule can be observed because of the difference in color between the stained lens capsule and the exposed, grey-white lens substance.
  • the outline of capsular defect can be visualized during the creation of a capsulorhexis, during removal of the lens substance by phacoemulsification, and during implantation of an intraocular lens in subsequent phases of the surgery.
  • a posterior capsulorhexis is made in the posterior lens capsule, before or after the implantation of an IOL.
  • a method according to the invention may be employed to stain the posterior lens capsule. Staining of the posterior lens capsule facilitates a controlled opening of the posterior capsule without damaging the anterior vitreous membrane.
  • Example II An in-vivo cataract extraction procedure is carried out on a human eye.
  • a corneal tunnel incision is made, the aqueous is aspirated and the anterior camber is filled with air.
  • a canula that is attached to a syringe containing the dye solution prepared in accordance with Example I is brought into the anterior chamber.
  • the tip of the canula is held against the anterior lens capsule, and a few drops of the dye solution is applied onto the anterior lens capsule.
  • the anterior chamber is flushed with Balanced salt solution (without dye) , until all visible traces of the dye are washed out. A bluish staining of the anterior lens capsule was visible.
  • a visco-elastic substance (HPMC Ocucoat, purchased from Storz, Clear Water, Florida, USA) is injected into the anterior chamber, and with a 30 gauge needle or fine forceps, a capsulorhexis is made.
  • the configuration of the capsulorhexis is controlled by visualization of the blue stained peripheral portion of the anterior capsule, whereas only the gray lenticular mass is seen in the area where the central portion of the anterior capsule has been excised.
  • a phacoemulsification procedure is performed to remove the lenticular tissue.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Surgery (AREA)
  • Prostheses (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Eyeglasses (AREA)
  • Optical Filters (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Absorbent Articles And Supports Therefor (AREA)

Abstract

The invention relates to a method for performing a capsulorhexis, wherein a lens capsule is stained using at least one dye, which dye is capable of staining tissue without diffusing through said tissue.

Description

Title: The use of a vital dye for facilitating surgical procedures for cataract extraction
The invention relates to the field of ocular surgery, in particular to surgical procedures for cataract extraction.
In the normal eye, the crystalline lens is located behind the iris, and in front of the corpus vitreum. The lens is transparent, biconvex, accounts for about 20 diopters of convergent refractive power of the eye, and it is composed of a capsule that encloses and encompasses the lens substance, i.e. the lens epithelium, the cortex, and the nucleus. A ring of zonular fibers, that extend from the ciliary body to the anterior part of the lens capsule, keeps the lens positioned within the eye.
The capsule is an elastic, type IV collagen basement membrane produced by the lens epithelial cells. The thickness of the capsule varies from 4-24 μm, with a thickness of about 14 μm at its anterior part, 24 μm at its equatorial part, and about 4 μm at its posterior part. Because of its transparency, and because its refractive index nearly equals the lens substance, the lens capsule can not be discriminated from the lens substance, except with the use of a slit-lamp at high magnification.
The lens substance may become less transparent, i.e. a cataract may develop, due to aging or to a wide variety of ocular or systemic pathological disorders or diseases. Affected portions of the lens substance may differ with the type of disorder, but in most cases the optical and/or refractive functions of the lens are compromised, for example a decreased visual acuity, a decreased contrast sensitivity, an accommodation loss, etc.
To restore the optical pathway, cataract surgery may be performed to remove the opaque lenticular mass. Although various surgical techniques are available, extracapsular cataract extraction techniques, the Blumenthal technique, or phacoemulsification are most often used. With all techniques, the anterior chamber of the eye is opened through a peripheral corneal, limbal or scleral incision, the anterior lens capsule is opened, and the lens substance is removed, while leaving the peripheral rim of the anterior lens capsule as well as the capsular equatorial and posterior portions in-situ. The empty lens capsule forms a capsular 'bag' that can be used to support a synthetic intraocular implant lens (IOL) , so that an IOL is positioned 'in the bag1.
Various techniques are used to open the anterior lens capsule, i.e. the excision of a portion of the anterior lens capsule, with or without the use of a viscous or viscoelastomeric substance, for example the can-opener technique, the envelop technique, the capsulotomy, and the continuous circular capsulorhexis. To visualize the capsular defect during the opening of the capsule, the red fundus reflex, the co-axial light of an operating microscope that is reflected from the posterior pole of the eye, is commonly used. When retroillumination is absent, for example with dense cataracts, heavily pigmented fundi or a combination of both, it is often not or only hardly possible to discriminate the anterior capsule from the underlying lens tissue.
Visualization of the defect in the anterior capsule during the opening of the lens capsule is an important step in the surgical procedure, because the mechanical traction forces which the capsule can withstand during surgery, vary with the configuration of the capsular opening. For example, in phacoemulsification a continuous circular capsulorhexis is commonly performed, because a circular configuration of the capsular opening can withstand best the surgical manipulations within the lens capsule during the removal of the lens substance. Improper visualization of the anterior lens capsule during the performance of a capsulorhexis may be responsible for a risk of a radial tear toward or beyond the equator of the lens capsule, and associated complications, for example vitreous loss, or a dropped nucleus. Furthermore, in a subsequent phase of the surgery the outline of the opening in the anterior lens capsule is often difficult to visualize. During the removal of the lens substance in phacoemulsification a useful red fundus reflex is nearly always absent, because the lenticular tissue becomes opaque. However, during phacoemulsification it still is important that the rim of the capsulorhexis is not damaged, so that the capsular integrity is maintained during the surgical manipulations within the capsule. For example, an inadvertent touch of the rim with the tip of the phacoemulsification hand piece or an overextension of the capsule during dividing the lenticular substance, may damage the rim of the capsulorhexis. Again, the damaged rim may give a greater risk of a radial tear toward the equator and associated complications, especially because the damage to the rim of the capsulorhexis may not be noticed during surgery .
During implantation of an IOL, the rim of the anterior capsule must be visualized to place the haptics of the IOL in between the anterior and posterior portions of the lens capsule. In this phase of the surgery, the anterior capsular rim can often be seen with the use of the red fundus reflex. To determine if a haptic(s) is positioned underneath the anterior capsular rim, the IOL is manipulated in such a way that the displacement of the capsular rim by the haptic or optic of the IOL indicates the position of the IOL relative to the capsule. In cases where a useful red fundus reflex is absent, as mentioned above, it becomes difficult to determine the position of the IOL relative to the capsule. Thus, there is a risk of the IOL being inserted in the area between the iris and the anterior lens capsule, for example the ciliary sulcus. Improper positioning of an IOL (that was designed to fit into the capsular bag) may be complicated by dislocation of the IOL after surgery.
In a letter to the Editor of the Journal of Cataract and Refractive Surgery (Hoffer KJ, McFarland JE,
"Intracameral subcapsular fluorescein staining for improved visualization during capsulorhexis in mature cataracts", J Cataract Refract Surg 1993 ; 19 : 566) , K.J. Hoffer and J.E. McFarland have addressed the above problems associated with the poor visibility of the anterior capsule during the performance of the capsulorhexis, in particular in the presence of a mature cataract . They suggest that the problems may be overcome by injecting a solution of fluorescein underneath the anterior chamber. During the capsulorhexis, the capsule would be better visible due to it being stained by the fluorescein dye.
Fluorescein is a dye which is capable of diffusing through various tissue structures (see e.g. Brubaker RF, "Clinical evaluation of the circulation of aqueous humor", in Tasman W, Jaeger EA, "Duane's clinical Ophthalmology", Volume 3, Chapter 46, Philadelphia, JB Lippencott Co, 1994:1-11; or Friberg TR, "Examination of the retina: principles of fluorescein angiography" , in Albert DM, Jakobiec FA, "Principles and practice of ophthalmology", Volume 2, Philadelphia, WB Saunders Co, 1994 ; 697-718.) . Consequently, when used as suggested by Hoffer and McFarland, fluorescein will not only stain the anterior lens capsule, but also the material below said capsule, particularly as the fluorescein is injected underneath the anterior lens capsule. This means that both the anterior lens capsule as well as the underlying lenticular tissue are stained by the fluorescein dye. Thus, no difference in staining can be observed between the anterior capsule and the underlying tissue during the capsulorhexis, and the desired improved visibility is not, or not sufficiently, achieved. Moreover, it was noted by Hoffer and McFarland that the sodium hyaluronate, which is used during the operation to fill the anterior chamber of the eye, may become stained and may have to be replaced with fresh sodium hyaluronate . Of course, it is undesired to have to interrupt the course of the surgical procedure to replace the gel layer.
The present invention seeks to overcome the above described problems associated with poor visibility of the lens capsule during cataract surgery. It is an object of the invention to make it possible to visually distinguish the anterior lens capsule from the underlying lenticular material, so that the configuration of an opening in the anterior lens capsule can be better monitored during surgery, for example to prevent the development of a radial tear toward or beyond the equator of the lens capsule during the performance of a capsulorhexis.
Surprisingly, it has now been found that said object may be attained by using a specific dye or mixture of dyes, which is capable of staining tissue or a tissue component, e.g. a membrane, without diffusing through said tissue or component thereof. Hence, the invention relates to a method for performing a capsulorhexis, wherein an anterior lens capsule is stained using at least one dye, which dye is capable of staining tissue without noticeably diffusing into said tissue.
In a method according to the invention, the outer surface of the anterior lens capsule is selectively stained, by which is meant that the lenticular material beneath the anterior lens capsule, is not noticeably stained. Accordingly, during the opening of the anterior lens capsule, a clear distinction can be observed between the portion of the anterior lens capsule, that is being removed, and the underlying lenticular material. This distinction facilitates the controlled opening of the anterior capsule, and reduces the risk of inadvertent damage to the capsule, for example a radial tear toward or beyond the equator of the lens .
It has been observed that the staining of the anterior lens capsule does not have a detrimental effect on the tissue with which the dye is contacted. Furthermore, it has been observed that shortly after the surgical procedure has been completed, substantially all visible traces of the dye have disappeared. Thus, a patient undergoing a cataract extraction involving a staining of the anterior lens capsule in accordance with the invention experiences no more distress or undesired side effects as when a conventional surgical procedure, not involving staining, is employed.
Furthermore, undesired staining of the intraocular structures other than the anterior lens capsule does not, or not to an adverse extent, occur. Staining of the sodium hyaluronate gel, that is applied after rinsing the dye from the anterior chamber, also does not, or not to an adverse extent, occur. As has been mentioned above, in a method according to the invention, the anterior lens capsule is stained using a dye. An important aspect of the invention is that a dye is used which is capable of staining tissue without diffusing into or through said tissue. Suitable dyes having this capability further should have sufficient coloring, or staining capacity at concentrations which are physiologically and toxicologically acceptable. In other words, the minimum amount of dye which is necessary to provide sufficient staining for a useful coloring to be visible should so be low that no, or hardly any, adverse toxic effects occur. Preferably, the dye is not or hardly endothelial toxic. It is further preferred, that substantially no traces of the dye are present in the eye, shortly after the cataract extraction procedure has been completed. As a result, there is hardly any risk of the patient experiencing any irritation of the cornea (corneal edema) or another part of the eye.
Particularly good results have been achieved using a dye having the formula (I)
Figure imgf000009_0001
wherein R. and R2 are the same or different arylgroups, and wherein R3 and R4 are independently chosen from hydrogen, methyl, ethyl, methoxy, amino, hydroxyl , and sulfonate. R. and R2 are preferably the same and formed by substituted naphtylgroups . Preferably, the naphtylgroups are substituted with one or more of sulfonate groups, amino groups and hydroxyl groups .
In a highly preferred embodiment, the dye is chosen from the group of trypan blue, trypan red and brilliant crysyl blue. It has been found that these dyes provide a clearly visible staining at very low amounts. Also, they have an extremely advantageous toxicity profile. More preferably, the dye is trypan blue.
Of course it is also possible to use mixtures of the above dyes as long as the resulting mixture is capable of achieving a color of the anterior lens capsule which can be easily distinguished from the color of the material below said capsule.
The dye is preferably used as a physiologically compatible solution. In a particularly preferred embodiment, the dye is formulated in an aqueous salt solution, which is isotone with ocular fluid. The salt is preferably sodium chloride, sodium phosphate, potassium chloride, calcium chloride, magnesium chloride, or a combination thereof. Suitable examples are Balanced salt solution or Hartmann's lactated Ringer's solution (Nuijts RMMA, Edelhauser HF, Holley GP, "Intraocular irrigating solutions: a comparison of Hartmann's lactated Ringer's solution, BSS and BSS plus", Clin. Exp . Ophtamol . , vol. 233 (1995), pp. 655-661). In accordance with this embodiment, the salt concentration will be in the range of 0.8 to 1.0 wt.%, based on the weight of the solution.
It is further preferred that the solution has a neutral pH, i.e. a pH between 6.5 and 7.5. The skilled person will be able to select a suitable buffer, which has the properties to be of use in opthtalmic applications. An example of a suitable buffer is phosphate buffered NaCl , commercially available at NPBI , Emmer-Compascuum, The Netherlands
In certain cases, depending on the desired manner of applying the dye solution to the anterior lens capsule, it may be desired to formulate said solution as a dispersion, or a viscous or viscoelastomeric solution, for example hyaluronic acid (see WO-A-96/32929) . It will be well within the standard expertise of the skilled person to select a suitable form for the solution. For instance, a higher viscosity may be desired in order to reduce the tension on the lenticular capsule during the capsulorhexis or to protect the cornea.
The concentration of the dye or the mixture of dyes in the solution will preferably be between 0.001 and 2 wt.%, more preferably between 0.01 and 0.1 wt.%, based on the weight of the solution. Within this range, the concentration may be adapted to the toxicity and coloring characteristics of the dye used. It is preferred that such an amount is chosen that an optimal staining effect is achieved, while at the same time the risk of possible damage to the eye or any part thereof due to the toxicity of the dye is minimized.
A method according to the invention is preferably employed as part of a surgical procedure for cataract extraction. After the eye is opened, for example by making a scleral or corneal tunnel incision, the aqueous (ocular fluid) is aspirated and the anterior camber is filled with air. A few drops of the above described solution comprising the dye in an appropriate concentration is applied onto the anterior lens capsule. The application of the solution may be carried out by bringing a canula that is attached to a syringe containing the dye into the anterior chamber, and to inject a few drops of the dye, generally less than 1 ml, onto the anterior lens capsule.
The anterior chamber is filled with air, so that the concentration of the dye in the solution is not lowered by the aqueous. As an alternative the dye can be administered in a higher concentration into the aqueous, or a dispersion of the dye in a viscous or viscoelastomeric solution can be used.
Preferably, the excess dye is washed out by irrigating the anterior chamber, leaving a faint but clear staining of the anterior lens capsule, after which the surgery can be continued using routine techniques. The irrigation may be carried out by using Balanced salt solution or any other solution that is commonly used in intraocular surgical procedures . After the anterior lens capsule has been stained, the capsule can be opened using routine surgical techniques. Independent of whether a red fundus reflex is present, the defect in the capsule can be observed because of the difference in color between the stained lens capsule and the exposed, grey-white lens substance. For example, the outline of capsular defect can be visualized during the creation of a capsulorhexis, during removal of the lens substance by phacoemulsification, and during implantation of an intraocular lens in subsequent phases of the surgery. In selected cases that may have an increased risk of the development of after-cataract, a posterior capsulorhexis is made in the posterior lens capsule, before or after the implantation of an IOL. In these cases, a method according to the invention may be employed to stain the posterior lens capsule. Staining of the posterior lens capsule facilitates a controlled opening of the posterior capsule without damaging the anterior vitreous membrane.
The invention will now be elucidated by the following, non-restrictive examples.
Example I
1 g of Trypan blue powder (Gurr, BDH Laboratory Supplies, Poole, United Kingdom) is dissolved in 1000 ml (1 liter) of Balanced salt solution (an aqueous solution of 0.9% NaCl) to obtain a concentration of 0.1 wt.% dye in solution. From the solution, 0.5 ml is drawn into a syringe, and a canula is attached to the syringe.
Example II An in-vivo cataract extraction procedure is carried out on a human eye. A corneal tunnel incision is made, the aqueous is aspirated and the anterior camber is filled with air. A canula that is attached to a syringe containing the dye solution prepared in accordance with Example I is brought into the anterior chamber. The tip of the canula is held against the anterior lens capsule, and a few drops of the dye solution is applied onto the anterior lens capsule. Then, the anterior chamber is flushed with Balanced salt solution (without dye) , until all visible traces of the dye are washed out. A bluish staining of the anterior lens capsule was visible.
A visco-elastic substance (HPMC Ocucoat, purchased from Storz, Clear Water, Florida, USA) is injected into the anterior chamber, and with a 30 gauge needle or fine forceps, a capsulorhexis is made. The configuration of the capsulorhexis is controlled by visualization of the blue stained peripheral portion of the anterior capsule, whereas only the gray lenticular mass is seen in the area where the central portion of the anterior capsule has been excised. After completion of the capsulorhexis, a phacoemulsification procedure is performed to remove the lenticular tissue.

Claims

Eur 4628Claims
1. A method for performing a capsulorhexis, wherein a lens capsule of an eye is stained using at least one dye, which dye is capable of staining tissue without diffusing through said tissue.
2. A method according to claim 1, wherein the lens capsule is the anterior lens capsule.
3. A method according to claim 1 or 2 , wherein the anterior lens capsule is stained by injecting the dye onto the capsule.
4. A method according to any of the preceding claims, wherein the method is part of a surgical procedure for cataract extraction.
5. A staining composition suitable for use in a method according to any of the preceding claims, which composition comprises at least one dye which is capable of staining tissue without diffusing through said tissue.
6. A staining composition according to claim 5, wherein the dye is chosen from the group of trypan blue, trypan red and brilliant crysyl blue.
7. A staining composition according to claim 5 or 6, wherein the composition has the form of a physiologically compatible solution.
8. A staining composition according to claim 7, wherein the at least one dye is present in a concentration between 0.001 and 2 wt.%, based on the weight of the solution.
9. A staining composition according to claims 5-8, which further comprises between 0.8 and 1.0 wt.%, based on the weight of the solution, of a salt.
10. Use of at least one dye, which dye is capable of staining tissue without diffusing through said tissue, for the manufacture of a composition for staining an anterior lens capsule of an eye in a method for performing a capsulorhexis .
PCT/NL1999/000284 1998-05-08 1999-05-07 The use of a vital dye for facilitating surgical procedures for cataract extraction WO1999058160A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SI9930298T SI1075285T1 (en) 1998-05-08 1999-05-07 The use of a vital dye for facilitating surgical procedures for cataract extraction
DK99921291T DK1075285T3 (en) 1998-05-08 1999-05-07 Use of a vital dye to facilitate surgical procedures for cataract extraction
BR9910287-0A BR9910287A (en) 1998-05-08 1999-05-07 Use of vital dye to facilitate cataract extraction surgical procedures
EP99921291A EP1075285B1 (en) 1998-05-08 1999-05-07 The use of a vital dye for facilitating surgical procedures for cataract extraction
AU38537/99A AU758951C (en) 1998-05-08 1999-05-07 The use of a vital dye for facilitating surgical procedures for cataract extraction
DE69905871T DE69905871T2 (en) 1998-05-08 1999-05-07 USE OF A DYE TO EASIER LENS EXTRACTION IN CATARACT
CA002331605A CA2331605C (en) 1998-05-08 1999-05-07 The use of a vital dye for facilitating surgical procedures for cataract extraction
AT99921291T ATE234118T1 (en) 1998-05-08 1999-05-07 USE OF A DYE TO FACILITATE LENS EXTRACTION IN CATARACT
PL99343924A PL194442B1 (en) 1998-05-08 1999-05-07 The use of a vital dye for facilitating surgical procedures for cataract extraction
JP2000548011A JP3469199B2 (en) 1998-05-08 1999-05-07 Use of vital dyes to facilitate surgical procedures for cataract extraction
US09/708,386 US6720314B1 (en) 1998-05-08 2000-11-08 Use of a vital dye for facilitating surgical procedures for cataract extraction
AU2003208122A AU2003208122A1 (en) 1998-05-08 2003-07-03 The use of vital dye for facilitating surgical procedures for cataract extraction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98201542.2 1998-05-08
EP98201542A EP0963759A1 (en) 1998-05-08 1998-05-08 The use of a vital dye for facilitating surgical procedures for cataract extraction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/708,386 Continuation US6720314B1 (en) 1998-05-08 2000-11-08 Use of a vital dye for facilitating surgical procedures for cataract extraction

Publications (1)

Publication Number Publication Date
WO1999058160A1 true WO1999058160A1 (en) 1999-11-18

Family

ID=8233705

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL1999/000284 WO1999058160A1 (en) 1998-05-08 1999-05-07 The use of a vital dye for facilitating surgical procedures for cataract extraction

Country Status (16)

Country Link
US (1) US6720314B1 (en)
EP (2) EP0963759A1 (en)
JP (1) JP3469199B2 (en)
KR (1) KR100642852B1 (en)
AT (1) ATE234118T1 (en)
AU (1) AU2003208122A1 (en)
BR (1) BR9910287A (en)
CA (1) CA2331605C (en)
DE (1) DE69905871T2 (en)
DK (1) DK1075285T3 (en)
ES (1) ES2197639T3 (en)
PL (1) PL194442B1 (en)
PT (1) PT1075285E (en)
SI (1) SI1075285T1 (en)
TR (1) TR200003280T2 (en)
WO (1) WO1999058160A1 (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001003620A1 (en) * 1999-07-09 2001-01-18 Minas Theodore Coroneo Use of trypan blue to visualise the anterior lens capsule of the eye
US6692526B1 (en) * 2000-03-15 2004-02-17 Michael E. Snyder Ophthalmological surgery colorant and delivery system
WO2004035091A1 (en) * 2002-10-14 2004-04-29 Fluoron Gmbh Production of a dye for colouring cells in the human or animal body
AU774292B2 (en) * 1999-07-09 2004-06-24 Minas Theodore Coroneo Use of trypan blue to visualise the anterior lens capsule of the eye
US7060297B2 (en) 2000-11-06 2006-06-13 Alcon, Inc. Carrageenan viscoelastics for ocular surgery
WO2006137341A1 (en) * 2005-06-22 2006-12-28 Kyoto University Agent for visualizing vitreous body
US7618619B2 (en) * 2000-03-07 2009-11-17 Medical Technology Transfer Holding B.V. Colored visco-elastic composition
EP2371395A1 (en) 2010-04-01 2011-10-05 Medical Technology Transfer Holding B.V. Staining Composition
WO2011122947A1 (en) 2010-04-01 2011-10-06 Medical Technology Transfer Holding B.V. Staining composition
EP2392355A1 (en) 2010-06-03 2011-12-07 Medical Technology Transfer Holding B.V. Staining composition
DE102012103097A1 (en) 2012-04-11 2013-10-17 Fluoron Gmbh Dye useful in kit and medical device used during e.g. cataract surgery for staining e.g. inner ophthalmic membrane, posterior/anterior lens capsule and cornea, and removing ophthalmic membrane, comprises Acid Violet 17 and carrier
US9764046B2 (en) 2008-12-25 2017-09-19 Canon Kabushiki Kaisha Labeling composition for intraocular tissue, labeling method of intraocular tissue, and screening method
US9801960B2 (en) 2008-12-25 2017-10-31 Canon Kabushiki Kaisha Probe for a biological specimen and labelling method and screening method using the probe
US9820886B2 (en) 2014-02-28 2017-11-21 Excel-Lens, Inc. Laser assisted cataract surgery
US9872797B2 (en) 2007-09-28 2018-01-23 Excel-Lens, Inc. Laser-assisted thermal separation of tissue
WO2018217088A1 (en) 2017-05-24 2018-11-29 D.O.R.C. Dutch Ophthalmic Research Center (International) B.V. Staining composition with improved staining intensity
US10206817B2 (en) 2014-02-28 2019-02-19 Excel-Lens, Inc. Laser assisted cataract surgery
US10231872B2 (en) 2014-02-28 2019-03-19 Excel-Lens, Inc. Laser assisted cataract surgery
US10327951B2 (en) 2014-02-28 2019-06-25 Excel-Lens, Inc. Laser assisted cataract surgery
WO2019212352A1 (en) 2018-05-04 2019-11-07 Fenelon Holland Holding B.V. Visualizing agent for visualizing hyaluronan
WO2021053609A1 (en) 2019-09-20 2021-03-25 Niios-Usa Inc. Donor overlay for treatment or alleviation of anterior corneal disorders

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060095B2 (en) * 2001-05-08 2006-06-13 Unisearch Limited Supplementary endo-capsular lens and method of implantation
WO2003043548A1 (en) * 2001-11-20 2003-05-30 Visco Dye Aps Visco dye
CN1964723B (en) * 2004-05-31 2011-06-22 千寿制药株式会社 Use of fine grain of macromolecule in preparing transparent tissue visualizing agent
EP1733744A1 (en) * 2005-06-17 2006-12-20 Ludwig-Maximilians-Universität München Method, dye and medicament for staining the internal limiting membrane and/or the capsule of an eye
EP2620144A1 (en) 2012-01-27 2013-07-31 Medical Technology Transfer Holding B.V. Staining Composition
DE102013006597A1 (en) * 2013-04-17 2014-10-23 Jean-Pierre Corlay Isotonic solution for insertion into the capsular bag of the eye in ophthalmological operations
US20150265468A1 (en) * 2014-03-21 2015-09-24 Carl Zeiss Meditec Ag Surgical system for opening the lens capsule in an eye
US11260135B2 (en) * 2018-04-13 2022-03-01 Excel-Lens, Inc. Dye enhanced visualization of cataract surgery

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB379650A (en) * 1931-04-16 1932-09-01 Ig Farbenindustrie Ag Manufacture of dye solutions capable of being injected for therapeutic purposes
US4350676A (en) * 1981-05-21 1982-09-21 Laties Alan M Ophthalmic use of carboxyfluorescein

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409904A (en) 1984-11-13 1995-04-25 Alcon Laboratories, Inc. Hyaluronic acid compositions and methods
US4778825A (en) * 1986-08-29 1988-10-18 The University Of Akron Macrophage stimulation by quadrol
US5066276A (en) 1988-06-21 1991-11-19 Alcon Laboratories, Inc. Method and apparatus for injecting viscous fluid into the eye to lift pre-retinal and post-retinal membrane with linear pressure control
US5273713A (en) 1989-01-18 1993-12-28 Laser Medical Technology, Inc. Water purification and sterilization process
US6186148B1 (en) * 1998-02-04 2001-02-13 Kiyoshi Okada Prevention of posterior capsular opacification
EP0974367A1 (en) 1998-05-08 2000-01-26 Gerrit Reinold Jacob Melles The use of a vital dye for facilitating surgical procedures for vitreo-retinal surgery
US6367480B1 (en) * 1999-07-09 2002-04-09 Minas Theodore Coroneo Methods for visualizing the anterior lens capsule of the human eye
US6533769B2 (en) * 2001-05-03 2003-03-18 Holmen Joergen Method for use in cataract surgery

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB379650A (en) * 1931-04-16 1932-09-01 Ig Farbenindustrie Ag Manufacture of dye solutions capable of being injected for therapeutic purposes
US4350676A (en) * 1981-05-21 1982-09-21 Laties Alan M Ophthalmic use of carboxyfluorescein

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
NORN M. S.: "Per operative trypan blue vital staining of corneal endothelium. Eight years follow up.", ACTA OPHTALMOLOGICA, vol. 58, 1980, pages 550 - 555, XP002082492 *
NORN M. S.: "Vital staining of corneal endothelium in cataract extraction", ACTA OPHTHALMOLOGICA, vol. 49, 1971, pages 725 - 733, XP002082493 *
SOLOMON K. D. ET AL: "Protective effect of the anterior lens capsule during extracapsular cataract extraction", OPHTHALMOLOGY, vol. 96, no. 5, May 1989 (1989-05-01), pages 591 - 597, XP002082494 *
TANIUCHI O.: "Intraocular penetration of trypan blue and of colloidal carbon administered by intraTenon's capsulary injection", FOLIA OPHTHALMOL. JPN., 1981, 32/1 (343-350), JAPAN, XP002082491 *

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU774292B2 (en) * 1999-07-09 2004-06-24 Minas Theodore Coroneo Use of trypan blue to visualise the anterior lens capsule of the eye
WO2001003620A1 (en) * 1999-07-09 2001-01-18 Minas Theodore Coroneo Use of trypan blue to visualise the anterior lens capsule of the eye
US7618619B2 (en) * 2000-03-07 2009-11-17 Medical Technology Transfer Holding B.V. Colored visco-elastic composition
US7070619B2 (en) 2000-03-15 2006-07-04 Snyder Michael E Ophthalmological surgery colorant and delivery system
US6692526B1 (en) * 2000-03-15 2004-02-17 Michael E. Snyder Ophthalmological surgery colorant and delivery system
US7060297B2 (en) 2000-11-06 2006-06-13 Alcon, Inc. Carrageenan viscoelastics for ocular surgery
WO2004035091A1 (en) * 2002-10-14 2004-04-29 Fluoron Gmbh Production of a dye for colouring cells in the human or animal body
DE20321721U1 (en) 2002-10-14 2009-04-09 Fluoron Gmbh Preparation of a staining agent for staining cells in the human or animal body
DE20321722U1 (en) 2002-10-14 2009-04-09 Fluoron Gmbh Preparation of a staining agent for staining cells in the human or animal body
DE10255601C5 (en) * 2002-10-14 2017-10-19 Fluoron Gmbh Use of a triphenylmethane dye for the manufacture of a stain for retinal and vitreous surgery
DE10255601B4 (en) 2002-10-14 2012-10-25 Fluoron Gmbh Use of a triphenylmethane dye for the manufacture of a stain for retinal and vitreous surgery
WO2006137341A1 (en) * 2005-06-22 2006-12-28 Kyoto University Agent for visualizing vitreous body
US9872797B2 (en) 2007-09-28 2018-01-23 Excel-Lens, Inc. Laser-assisted thermal separation of tissue
US9764046B2 (en) 2008-12-25 2017-09-19 Canon Kabushiki Kaisha Labeling composition for intraocular tissue, labeling method of intraocular tissue, and screening method
US9801960B2 (en) 2008-12-25 2017-10-31 Canon Kabushiki Kaisha Probe for a biological specimen and labelling method and screening method using the probe
EP2371395A1 (en) 2010-04-01 2011-10-05 Medical Technology Transfer Holding B.V. Staining Composition
US9579401B2 (en) 2010-04-01 2017-02-28 Medical Technology Transfer Holding B.V. Staining composition
WO2011122947A1 (en) 2010-04-01 2011-10-06 Medical Technology Transfer Holding B.V. Staining composition
US10426849B2 (en) 2010-04-01 2019-10-01 D.O.R.C. Dutch Ophthalmic Research Center (International) B.V. Staining composition
EP2392355A1 (en) 2010-06-03 2011-12-07 Medical Technology Transfer Holding B.V. Staining composition
DE102012103097A1 (en) 2012-04-11 2013-10-17 Fluoron Gmbh Dye useful in kit and medical device used during e.g. cataract surgery for staining e.g. inner ophthalmic membrane, posterior/anterior lens capsule and cornea, and removing ophthalmic membrane, comprises Acid Violet 17 and carrier
US10206817B2 (en) 2014-02-28 2019-02-19 Excel-Lens, Inc. Laser assisted cataract surgery
US10231872B2 (en) 2014-02-28 2019-03-19 Excel-Lens, Inc. Laser assisted cataract surgery
US10327951B2 (en) 2014-02-28 2019-06-25 Excel-Lens, Inc. Laser assisted cataract surgery
US9820886B2 (en) 2014-02-28 2017-11-21 Excel-Lens, Inc. Laser assisted cataract surgery
US10561531B2 (en) 2014-02-28 2020-02-18 Excel-Lens, Inc. Laser assisted cataract surgery
WO2018217088A1 (en) 2017-05-24 2018-11-29 D.O.R.C. Dutch Ophthalmic Research Center (International) B.V. Staining composition with improved staining intensity
WO2019212352A1 (en) 2018-05-04 2019-11-07 Fenelon Holland Holding B.V. Visualizing agent for visualizing hyaluronan
WO2021053609A1 (en) 2019-09-20 2021-03-25 Niios-Usa Inc. Donor overlay for treatment or alleviation of anterior corneal disorders

Also Published As

Publication number Publication date
EP1075285A1 (en) 2001-02-14
KR20010043431A (en) 2001-05-25
AU758951B2 (en) 2003-04-03
DE69905871T2 (en) 2004-02-26
DK1075285T3 (en) 2003-07-14
US6720314B1 (en) 2004-04-13
JP3469199B2 (en) 2003-11-25
TR200003280T2 (en) 2001-02-21
JP2002514471A (en) 2002-05-21
EP0963759A1 (en) 1999-12-15
CA2331605A1 (en) 1999-11-18
ATE234118T1 (en) 2003-03-15
SI1075285T1 (en) 2003-10-31
ES2197639T3 (en) 2004-01-01
AU2003208122A1 (en) 2003-08-07
PL194442B1 (en) 2007-05-31
PT1075285E (en) 2003-08-29
DE69905871D1 (en) 2003-04-17
AU3853799A (en) 1999-11-29
PL343924A1 (en) 2001-09-10
BR9910287A (en) 2001-01-09
CA2331605C (en) 2008-09-16
KR100642852B1 (en) 2006-11-03
EP1075285B1 (en) 2003-03-12

Similar Documents

Publication Publication Date Title
CA2331605C (en) The use of a vital dye for facilitating surgical procedures for cataract extraction
EP2552491B1 (en) Staining composition for use in a method of eye surgery
Melles et al. Trypan blue capsule staining to visualizethe capsulorhexis in cataract surgery
EP2620144A1 (en) Staining Composition
EP1389989A1 (en) Method for use in cataract surgery
WO2003043548A1 (en) Visco dye
AU2018273448B2 (en) Staining composition with improved staining intensity
EP2371395A1 (en) Staining Composition
AU2015202819B2 (en) Staining composition
EP2392355A1 (en) Staining composition
Agrawal et al. Use of trypan blue to confirm the patency of filtering surgery
JP3953322B2 (en) Use of trypan blue to visualize the anterior lens capsule of the eyeball
Gupta et al. Trypan Blue Dye as an Adjunct to Cataract Surgery
JP2012236077A (en) Use of trypan blue for visualizing anterior lens capsule of human eyeball

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2331605

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 09708386

Country of ref document: US

Ref document number: 1020007012468

Country of ref document: KR

Ref document number: 2000/03280

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 38537/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999921291

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999921291

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007012468

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1999921291

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 38537/99

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 1020007012468

Country of ref document: KR